


Era of magnesium for orthopaedics and traumatology begins in India

08 October 2021 | News

Patient potential already more than three times as large as the entire EU



The Central Drugs Standard Control Organisation (CDSCO) has granted German firm Syntellix the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market.

In one fell swoop, this increases global market access and the amount of potential patients who can be treated with the company's MAGNEZIX® implants by an additional 1.38 billion to now 3.8 billion people.

The game-changer market of India, with its exceptionally good doctors and in many cases ultra-modern hospitals, plays a decisive role in the global substitution of conventional implant technologies in favour of the MAGNEZIX® platform technology.

In addition, India is ideally suited for collecting further clinical data and conducting clinical trials and will also contribute significantly to the development of new, additional Syntellix products.